Treatment

ELOCTA 250 IU Powder and solvent for solution for injection clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic use (Phase IV)
An 18-month low-interventional prospective, multicentre study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa
This study looks at how well different medicines (Elcocta and Alprolix) help people with haemophilia A or B protect their joints. Researchers will follow participants for 18 months to see if these treatments prevent joint problems.
For: Hemophilia A and B
Hungary · Ireland · Czechia